glp-1 agonists and pancreatitis GLP-1–Based Therapies: The Dilemma of Uncertainty GLP-1 Receptor Agonists | New

International Immunopharmacology

As competition in the obesity drug market heats up, Novo Nordisks obesity pipeline positions it as a frontrunner in delivering life-changing solutions for millions worldwide

This suggests inhibition of vagal cholinergic input into the stomach with a concomitant increase in gastric volume, though the exact mechanism is not clear

While these drugs were not initially approved for weight management, a small proportion of patients were using them to support weight loss, with doctors prescribing these off-label (off-label prescribing is where a drug is prescribed for a reason other than the one it is licensed for) in these cases, GLP-1RAs were given to people without diabetes but with a high body mass index (BMI)

doi: 10.1126/science.adt0548

Hormone and Metabolic Research